Overview

Fed Bioequivalence Study of 2 Metformin 500 mg Prolongued Release Tablets in 28 Healthy Male and Female Volunteers

Status:
Completed
Trial end date:
2019-07-03
Target enrollment:
Participant gender:
Summary
The objective of the study is to compare the bioavailability of the Test and Reference products both containing Metformin 500 mg prolonged release tablets (MFM) in healthy male and female volunteers under fed conditions and to assess the bioequivalence of these products based on confidence acceptance intervals of 80.00% to 125.00% for AUC(o-t)and Cmax of MFM as primary endpoints.
Phase:
Phase 1
Details
Lead Sponsor:
Joint Stock Company "Farmak"
Treatments:
Metformin